Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers".

Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, DiBiase RM, Jia DT, Balabanov R, Ho SU, Batra A, Liotta EM, Koralnik IJ. · 2021

Read Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". by Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, DiBiase RM, Jia DT, Balabanov R, Ho SU, Batra A, Liotta EM, Koralnik IJ. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8108421.txt.

Introduction

Graham and co-authors study the first 100 patients at their Neuro-COVID clinic who were never hospitalized. Half had lab-confirmed SARS-CoV-2 infection, half tested negative. All had neurologic symptoms lasting over six weeks. The group skewed young and female, with an average age in the early forties. Their complaints painted a consistent picture of stalled recovery.

Brain fog led the list at 81% of patients reporting the symptom. Headache followed at 68%, then numbness or tingling at 60% of the group. Loss of taste and smell each touched over half. Fatigue gripped 85% of the whole group as well. Loss of smell split the two halves sharply: 74% of confirmed cases versus 36% of the test-negative group. Lab-positive patients scored worse on attention and working memory tests. Quality of life sagged in both groups alike. Time since onset did not predict feeling better.

Catalog record

CREATORGraham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, DiBiase RM, Jia DT, Balabanov R, Ho SU, Batra A, Liotta EM, Koralnik IJ.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8108421

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers” By Edith L Graham, Jeffrey R Clark, Zachary S Orban, Patrick H Lim, April L Szymanski, Carolyn Taylor, Rebecca M DiBiase, Dan Tong Jia, Roumen Balabanov, Sam U Ho, Ayush Batra, Eric M Liotta Published in: Annals of Clinical and Translational Neurology DOI: 10.1002/acn3.51350 ABSTRACT Abstract Objective Most SARS‐CoV‐2‐infected individuals never require hospitalization. However, some develop prolonged symptoms. We sought to characterize the spectrum of neurologic manifestations in non‐hospitalized Covid‐19 “long haulers”. Methods This is a prospective study of the first 100 consecutive patients (50 SARS‐CoV‐2 laboratory‐positive (SARS‐CoV‐2+) and 50 laboratory‐negative (SARS‐CoV‐2‐) individuals) presenting to our Neuro‐Covid‐19 clinic between May and November 2020. Due to early pandemic testing limitations, patients were included if they met Infectious Diseases Society of America symptoms of Covid‐19, were never hospitalized for pneumonia or hypoxemia, and had neurologic symptoms lasting over 6 weeks. We recorded the frequency of neurologic symptoms and analyzed patient‐reported quality of life measures and standardized cognitive assessments. Results Mean age was 43.2 ± 11.3 years, 70% were female, and 48% were evaluated in televisits. The most frequent comorbidities were depression/anxiety (42%) and autoimmune disease (16%). The main neurologic manifestations were: “brain fog” (81%), headache (68%), numbness/tingling (60%), dysgeusia (59%), anosmia (55%), and myalgias (55%), with only anosmia being more frequent in SARS‐CoV‐2+ than SARS‐CoV‐2‐ patients (37/50 [74%] vs. 18/50 [36%]; p < 0.001). Moreover, 85% also experienced fatigue. There was no correlation between time from disease onset and subjective impression of recovery. Both groups exhibited impaired quality of life in cognitive and fatigue domains. SARS‐CoV‐2+ patients performed worse in attention and working memory cognitive tasks compared to a demographic‐matched US population (T‐score 41.5 [37, 48.25] and 43 [37.5, 48.75], respectively; both p < 0.01). Interpretation Non‐hospitalized Covid‐19 “long haulers” experience prominent and persistent “brain fog” and fatigue that affect their cognition and quality of life. INTRODUCTION As of 10 March 2021, severe acute respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) has led to over 117 million confirmed infections and 2.6 million deaths from coronavirus disease‐2019 (Covid‐19) worldwide. 1 Although SARS‐CoV‐2 manifests primarily with respiratory tract infections and flu‐like symptoms, Covid‐19 is now recognized as a multi‐organ disease often involving the nervous system. Neurologic manifestations of varying severity 2 , 3 , 4 have been reported in 36.4–82.3% of hospitalized Covid‐19 patients worldwide. 5 , 6 , 7 Neurologic, pulmonary, cardiac, and gastrointestinal dysfunction may persist in the post‐acute phase and constitute a “long Covid” syndrome, 8 , 9 which has also recently been called the syndrome of “post‐acute sequelae of SARS‐CoV‐2 infection” (PASC). 10 In addition, approximately 80% of infected individuals have limited and transient respiratory symptoms, and do not require hospitalization for pneumonia or hypoxemia. 11 , 12 Nevertheless, some develop persistent and debilitating symptoms despite a relatively mild illness at onset, and they are known as Covid‐19 “long haulers.” 4 , 13 , 14 Whereas some “long haulers” were found to be positive for SARS‐CoV‐2 RNA by RT‐PCR at symptom onset, many did not fulfill the criteria for testing at the beginning of the pandemic, or tested negative at a time when respiratory symptoms had subsided. In addition, some “long haulers” did not have detectable antibodies to SARS‐CoV‐2 when the first serological test (Abbott) became available commercially. Whether this represents false negative results due to transient production of antiviral antibodies or the limited sensitivity of the assay is currently unclear. 15 , 16 , 17 We sought to characterize the range of neurologic manifestations in non‐hospitalized “long haulers” presenting at our Neuro‐Covid‐19 clinic, in both SARS‐CoV‐2 laboratory‐positive (SARS‐CoV‐2+) and laboratory‐negative (SARS‐CoV‐2‐) individuals. Furthermore, cognitive dysfunction, identified as “brain fog” by “long haulers,” has been prominently mentioned in the media and in other studies. 8 , 13 , 18 , 19 Therefore, we prospectively evaluated multiple domains of cognitive function and self‐reported quality of life measures using validated instruments in Covid‐19 “long haulers”. SUBJECTS/MATERIALS AND METHODS Patients We prospectively analyzed 100 patients (the first 50 consecutive SARS‐CoV‐2 laboratory‐positive [SARS‐CoV‐2+] and the first 50 consecutive SARS‐CoV‐2 laboratory‐negative [SARS‐CoV‐2‐] individuals who met study inclusion criteria) seen at the Neuro‐Covid‐19 clinic of Northwestern Memorial Hospital, Chicago, IL between 13 May and 11 November 2020. The first identified case of Covid‐19 in the United States was on 21 January 2020. 20 Patients were included if they had clinical manifestations of Covid‐19 compatible with Infectious Diseases Society of America (IDSA) guidelines starting in February 2020 or later, 21 but did not require hospitalization for pneumonia or hypoxemia, and had neurologic symptoms persisting at least 6 weeks from symptom onset. Covid‐19 diagnosis was confirmed by SARS‐CoV‐2 reverse transcription‐polymerase chain reaction (RT‐PCR) of nasopharyngeal swab and/or SARS‐CoV‐2 antibody testing in 50 SARS‐CoV‐2+ patients, whereas those tests showed negative results in 50 SARS‐Cov‐2‐ patients. SARS‐Cov‐2‐ patients meeting IDSA Covid‐19 symptom guidelines were included as a comparison group of patients with clinically suspected post‐acute viral syndrome. All laboratory, radiologic, and electrophysiologic assessments were performed as part of routine clinical care. This study was approved by our institutional review board (STU00212627). Procedures All patients were evaluated by an attending neurologist (IJK) assisted by a neuroimmunology fellow (ELG), nurse practitioners, and neurology residents. Patients from the entire United States could be seen in televisits only from 13 May to 1 July, due to pandemic lockdown, and in a mix of tele and in‐person visits thereafter. Medical records from patients located outside Illinois (including 21 states) were obtained and reviewed. Patient‐reported quality of life in cognition and fatigue domains was assessed using the validated Patient Reported Outcome Measurement Information System (PROMIS) assessment. 22 , 23 Patients presenting in‐person had the opportunity to complete a cognitive function evaluation with the National Institutes of Health (NIH) Toolbox v2.1 instrument, including assessments of: processing speed (pattern comparison processing speed test); attention and executive memory (inhibitory control and attention test); executive function (dimensional change card sort test); and working memory (list sorting working memory test). 24 , 25 , 26 , 27 Both PROMIS and NIH Toolbox results are expressed as T‐scores adjusted for age, education, gender, and race/ethnicity with a score of 50 representing the normative mean/median of the US reference population with a standard deviation of 10. Lower cognition T‐scores indicate worse performance while higher fatigue T‐scores indicate greater fatigue severity. Statistical analysis Data were summarized as number of patients (frequency), mean (standard deviation) for normally distributed variables, and median (interquartile range [IQR]) for non‐normally distributed variables. Group differences were assessed using Fisher’s exact test, unpaired t‐test, and Wilcoxon rank‐sum test. Correlations between variables were assessed with Pearson’s or Spearman’s correlation tests, as appropriate. To determine if results of PROMIS and NIH Toolbox domains differed from expected, patient group T‐scores were compared to the demographic‐matched normative US population median of 50 using one‐sample Wilcoxon signed‐rank tests. Two‐sided p ≤ 0.05 was considered significant and all analyses were performed in GraphPad Prism version 9.0.0. Study data were collected and managed using REDCap electronic data capture tools. RESULTS Patient demographics, SARS‐CoV‐2 testing, and comorbidities We cared for 135 patients in the Neuro‐Covid‐19 clinic between 13 May and 11 November 2020. Thirty‐five patients did not meet criteria for study inclusion: 20 had been hospitalized for pneumonia or

Read the complete text